Immunocore to Participate in the Cantor Global Healthcare Conference
Immunocore Holdings plc (Nasdaq: IMCR), an innovative biotechnology company, has some exciting news. They are preparing to present at the highly regarded Cantor Global Healthcare Conference, a key event within the healthcare industry. This conference provides a vital stage for discussing the latest advances and innovations in biotechnology.
Conference Details
The presentation will take place on Thursday at 12:45 p.m. EDT. During this time, the management team will participate in a fireside chat. Everyone is encouraged to tune in as the company reveals insights into their groundbreaking research and development. You can find the live webcast on Immunocore’s official website in the ‘Events & Presentations’ section under the ‘Investors’ area. Plus, a limited-time replay will be available after the event, so those interested can catch up on the key takeaways.
About Immunocore’s Innovative Strategies
Immunocore is making a name for itself in the biotechnology industry with its revolutionary approach to immunotherapy. The company focuses on a distinctive class of treatments called TCR bispecific immunotherapies. This advanced platform, known as ImmTAX, harnesses the power of the immune system to fight diseases like cancer, autoimmune disorders, and infections.
Product Pipeline and Clinical Advancements
Immunocore has a strong pipeline that holds the potential to transform treatment options for patients. Currently, the company is advancing five clinical-stage programs targeting oncology and infectious diseases, along with pre-clinical programs aimed at autoimmune conditions. Their flagship product, KIMMTRAK, has received considerable approval for treating patients with specific types of uveal melanoma, offering hope to many individuals.
Leadership and Contact Information
At the core of Immunocore’s vision is a passionate team dedicated to delivering transformative health solutions. For media inquiries, Sébastien Desprez, Head of Communications, is available at +44 (0) 7458030732. For any investment-related questions, Clayton Robertson, Head of Investor Relations, can be reached at +1 (215) 384-4781. Both are enthusiastic about connecting with stakeholders and the public.
Connecting with Immunocore
Immunocore values engagement and communication. You can stay updated on their impactful journey by following them on Twitter at @Immunocore. This way, you’ll be informed about their latest developments and contributions in the biotechnology sector.
Frequently Asked Questions
What is the main focus of Immunocore's research?
Immunocore primarily focuses on developing TCR bispecific immunotherapies aimed at treating cancer, autoimmune disorders, and infectious diseases.
When will Immunocore present at the Cantor Global Healthcare Conference?
The presentation is scheduled for Thursday at 12:45 p.m. EDT, where management will conduct a fireside chat.
How can I access the live webcast of the presentation?
You can view the live webcast via the Immunocore website in the ‘Events & Presentations’ section located in the ‘Investors’ area.
What is KIMMTRAK and its importance?
KIMMTRAK is Immunocore’s leading therapy for patients who are HLA-A*02:01-positive and have unresectable or metastatic uveal melanoma. It has gained approval in several significant markets.
How can I contact Immunocore for inquiries?
If you have media inquiries, contact Sébastien Desprez at +44 (0) 7458030732. For investor relations, reach out to Clayton Robertson at +1 (215) 384-4781.
